Physician profile
Danielle E Parrish
NPI 1720043789
$7,826.40
in general payments reported to CMS, 2019-2025
52 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,649 · 2022: $976 · 2023: $918 · 2024: $1,208 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,018 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,017.63 |
| Education | $183.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,733.33 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $1,364.78 | 2021-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,014.62 | 2021-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Genzyme Corporation | $397.95 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $352.98 | 2023-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $268.07 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Merck Sharp & Dohme LLC | $223.44 | 2024-2025 | Zerbaxa, Keytruda, Winrevair |
| Insmed, INC. | $212.27 | 2021-2025 | Brinsupri, Arikayce |
| Grifols USA, LLC | $203.19 | 2021-2025 | Prolastin-C Liquid, Xembify |
| United Therapeutics Corporation | $200.72 | 2023-2025 | Tyvaso, Tyvaso |
| Genentech USA, INC. | $184.10 | 2021-2024 | Xolair, Actemra, Esbriet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.20 | 2021-2025 | Ofev |
| Mylan Specialty L.P. | $166.35 | 2024 | Yupelri |
| Amgen INC. | $104.86 | 2022-2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $92.57 | 2025 | Purified Cortrophin Gel |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.